SARS-COV-2 re-infection and incidence of post-acute sequelae of COVID-19 (PASC) among essential workers in New York: a retrospective cohort study
After surviving Coronavirus Disease 2019 (COVID-19), some people develop symptoms known as post-acute sequelae of COVID-19 (PASC). PASC is an emerging phenomenon yet to be fully understood, and identifying risk factors has been challenging.
News
Policy & Recommendations
ECDC launches RespiCompass, a scenario modelling hub for respiratory diseases
ECDC has launched an online platform, RespiCompass, which uses mathematical modelling to simulate respiratory disease dynamics under different scenarios.
Neurological post-COVID syndrome is associated with substantial impairment of verbal short-term and working memory
A substantial proportion of patients suffer from Post-COVID Syndrome (PCS) with fatigue and impairment of memory and concentration being the most important symptoms.
SARS-CoV-2 Infection and New-Onset Type 2 Diabetes Among Pediatric Patients, 2020 to 2022
Is a COVID-19 diagnosis associated with increased incident diagnoses of type 2 diabetes in children and adolescents?
Impact of twelve immunization-preventable infectious diseases on population health using disability-adjusted life years (DALYs) in Spain
The objective of this study is to estimate the burden of selected immunization-preventable infectious diseases in Spain.
Inconsistent Increase in Age at Respiratory Syncytial Virus Hospitalization of Children Aged 2 Years During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: A Retrospective Multicenter Study in 4 European Countries
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic disrupted respiratory syncytial virus (RSV) seasonality.
First encounter with SARS-CoV-2: immune portraits of COVID susceptibility
More than four years after the start of the COVID-19 pandemic, and the mass mobilization of the scientific community.
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
Safe and effective vaccines against SARS-CoV-2 were developed in less than 1 year.
|
9th Influenza Conference 2023
Scientific highlights of the 9th ESWI Influenza Conference
With promising developments in the field of respiratory viral infections, the conference sessions covered hot topics on seasonal, pandemic, and zoonotic influenza viruses, as well as other respiratory viruses such as RSV and SARS-CoV-2.
The hinge-engineered IgG1-IgG3 hybrid subclass IgGh47 potently enhances Fc-mediated function of anti-streptococcal and SARS-CoV-2 antibodies
Streptococcus pyogenes can cause invasive disease with high mortality despite adequate antibiotic treatments. To address this unmet need, we have previously generated an opsonic IgG1 monoclonal antibody, Ab25, targeting the bacterial M protein.
The influenza landscape and vaccination coverage in older adults during theSARS-Cov-2 pandemic: data from Several European Countries and Israel
While influenza and the common cold are both contagious viral respiratory tract illnesses, influenza can be a serious disease that could lead to severe complications and unfavorable outcomes due to broader consequences.
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1
COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of the SARS-CoV-2 XBB.1.5 subvariant.
